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Abstract 
 
Objectives. 
We explore how broader aspects of a treatment’s value and the impact of the condition on 
patients not captured by routine Health Technology Assessment (HTA) methods using 
clinical and economic evidence, defined as “other considerations”, may influence HTA 
processes in different settings.  
 
Methods. 
Countries included were England, Scotland, Sweden, and France. Data sources were the 
publicly available reports on HTA recommendations. Ten drugs with EMA orphan 
designation and appraised in England were selected. Qualitative thematic analysis was used 
to systematically identify and code all “other considerations” based on a previously validated 
methodological framework, which also coded whether it was provided by stakeholders, and 
how it influenced the decision.  
 
Results. 
A classification framework of scientific and social value judgments was developed and used 
throughout the study. 125 “other considerations” were identified and grouped into ten 
subcategories based on the information provided. 18% to 100% of these, depending on the 
agency, were put forward as one of the main reasons for the final decision potentially 
contributing to accepting a higher ICER or uncertain evidence. Some of these were non-
quantified or non-elicited and pertained to the assessor’s judgment. A taxonomy of these 
value judgments was created to be used in future cases. Results also contributed to better 
defining the determinants of social value and improving accountability for reasonableness.  
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Conclusions. 
The systematic identification of the scientific and social value judgments enables to better 
understanding the dimensions of value, which can be used to improve their transparency and 
consistent use across decisions and settings.  
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Introduction 
Healthcare decision-makers are responsible for resource allocation decisions with the primary 
objective to maximise health and social welfare in the whole population.(1) Health 
technology assessment (HTA) helps make such decisions about whether to reimburse a new 
treatment by providing guidance on the efficient use of resources, ultimately, optimising 
patient access to these. It relies on systematic approaches to appraising evidence about the 
value of using this treatment in terms of benefits (and costs) in real world settings, while 
including considerations of social, ethical and legal aspects to inform coverage for this 
technology.(2) 
 
Routine HTA methods that rely on clinical (and economic) evidence may not adequately 
capture all the important considerations of a treatment’s value and the impact of the condition 
on patients in real world settings.(3) This is partly because HTA is undertaken at the time of 
the treatment’s launch onto the market when evidence is often incomplete since real world 
evidence is generally not available. HTA bodies also tend to rely on experimental evidence 
collected within controlled environments (e.g. RCTs),(4) despite their limitations in capturing 
effectiveness.(5) In such cases, scientific judgments about the reliability, generalisability and 
meaningfulness of this evidence in the clinical context are made.(6, 7) Additionally, these 
processes also account for elicited societal preferences that refer to cases when society agrees 
to forego health in order to treat specific populations. Yet, decision-makers may grant 
preference for a treatment despite this preference not having been previously elicited by the 
general population; these would be considered as social value judgments.(6, 7) These 
judgments are usually made as part of the deliberative process of HTA, during which experts 
and key stakeholders are consulted and the evidence is discussed until a decision is taken.(8) 
The main criticisms of this process is the lack of “accountability for reasonableness” given 
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that there is not always a clear process to account for the inclusion of these forms of evidence 
in the assessment process, as well as the lack of consistency in accounting for these “other 
considerations”.(8-10) 
 
Drugs used to treat rare conditions with an orphan designation are often characterised by 
uncertainty and high incremental cost-effectiveness ratios (ICER), and are usually not cost-
effective.(11) This is a consequence of the difficulties in producing robust evidence due to 
the small patient populations and the heterogeneity of these conditions, as well as their high 
prices. These reimbursement decisions therefore rely on whether society is willing to forego 
health to the whole population in order to treat fewer patients with a rare condition.(12) Little 
evidence in support of a societal preference for rare conditions exists, and the few studies that 
attempted to elucidate this suggested the contrary when patients with more common diseases 
were denied treatment in order to treat fewer patients with a rare condition.(12-15) In such 
cases, these decisions partly rely on the decision-makers’ willingness to accept high ICERs 
based on additional factors that influence their judgment of (scientific and social) value, such 
as, for example, disease severity, the treatment’s orphan status, or to what extent evidence 
characterised by uncertainty is acceptable.(16) They also rely on the flexibility of these 
processes in, for example, their ability to implement managed entry agreements or the 
availability of separate funding programs (e.g. Cancer Drug Fund in England). It is somewhat 
different in France, where a procedure has been set up to expedite access to drugs for rare 
diseases, as a means to support development and dissemination of treatment for populations 
suffering from rare conditions.   
 
This study goes beyond the assessment of clinical and economic evidence into other areas 
that help explain value. Its purpose is to explore how broader aspects of a treatment’s value 
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and the impact of the condition on patients, not captured by routine HTA methods, influence 
these HTA processes in different countries. This is all the more important given that 
expectations from HTA bodies in terms of relative effectiveness may differ depending on 
drug and disease characteristics.(17) The subject of analysis was a sample of orphan drugs in 
four countries (England, Scotland, Sweden, and France), because of the greater uncertainty 
characterising these. We then examined whether the social value judgments revealed pertain 
to orphan drugs and under what circumstances do they have a preferential status.  
 
Methods 
Study sample 
Purposive sampling was used to select the study countries with the aim of having a good 
representation of different types of decision-making characteristics, in terms of: (a) the 
criteria used; (b) the perspective adopted; and (c) any existing elicited preferences (Table 1). 
The HTA agencies and their decision-making Committees included were: the Appraisal 
Committee of the National Institute for Health and Care Excellence (NICE) in England, the 
Scottish Medicines Consortium (SMC) in Scotland, the Dental and Pharmaceutical Benefits 
Board (TLV) in Sweden, and the Transparency Committee of the Haute Autorité de Santé 
(HAS) in France.  HAS assesses the drug’s medical benefit (Service Médical Rendu, SMR) 
to inform its coverage rate and the relative improvement in medical benefit (Amélioration du 
Service Médical Rendu, ASMR) to inform the pricing negotiation, ranking treatments in five 
levels.  Both the drug’s medical effectiveness (risk-benefit ratio) and its interest in terms of 
public health (ISP) are accounted for in the SMR assessment.  No economic modelling was 
done by HAS at the time of the sampled drugs’ appraisals.  For cost considerations, NICE 
and SMC agencies adopt a health service perspective and TLV a societal perspective. 
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Ten drug and indication pairs were selected, with the following criteria: (a) with an orphan 
drug designation from the European Medicines Agency, (b) appraised by the NICE Single 
Technology Appraisal process until December 2012, and (c) by at least two other study 
countries.  
 
Data collection and analysis 
 
This empirical study applied a validated methodological framework enabling the systematic 
identification and comparison of the criteria driving HTA decisions for the same drugs in 
different countries through a mixed methods research design comprising three key stages: the 
evidence appraised, its interpretation and its influence on the final recommendation.(17) In 
this paper, we focus on the results from the interpretation of the evidence component. 
Specifically, we wanted to see what elements beyond cost-effectiveness, cost, effectiveness 
and safety were raised by the HTA agencies and whether these played a role on the decision-
making.  
 
Thematic analysis was conducted to identify and code all the “other considerations” 
accounted for during the appraisal process and recorded in the appraisal reports. Bottom-up 
coding was performed, where codes were inductively created while examining the data to 
summarise what was put forward and categorise this data depending on the type of 
information provided.(18) The section of text coded included all the text referring to the 
“other consideration”. For example, the whole section of text referring to the scarcity in the 
treatments alternatives available would be coded as “few treatment alternatives”. Codes were 
then categorised into subcategories depending on the type of information provided, and 
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recorded in a coding manual.(17) These were clustered into two groups: disease 
characteristics and treatment characteristics. Coding was iterative and flexible to ensure the 
transferability of codes to other drugs and countries, and additional codes were created with 
newly identified “other considerations”. Coding was conducted by the lead author. Coding 
reliability was tested by a colleague expert in Health Policy, who re-categorised each 
individual code into one of these. Where differences were observed, adjustments were made 
and documented. The validity of the data collected was established through feedback from 
external experts, including from HTA bodies (who have been presented most of this work), 
HTA experts from the Advance-HTA Consortium, and fellow peers when presented at 
conferences. 
 
Coding was performed vertically and horizontally. In the former, all “other considerations” 
were coded in a systematic manner as prescribed in the coding manual(17). In the latter, all 
“other considerations” were double coded with: (a) if it was put forward as one of the main 
reasons for the decision, (b) source of the information provided (e.g. experts), and (c) if it 
was accounted for in the other countries. The data collected qualitatively was then 
quantitatively analyzed to determine: (a) the type and frequency of “other considerations” 
accounted for; (b) cases when these were one of the main reasons for the decisions; (c) how 
they were provided; and (d) how they compared across agencies. The qualitative statistical 
software NVivo 10 was used for the data collection and analysis,(19) and Excel for further 
data analysis. Data sources consisted in the HTA reports publicly available from each HTA 
body, complemented with a selected review of the literature and input from key stakeholders 
(HTA bodies, Advance-HTA Consortium, other peers). 
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For each sub-category of “other considerations”, we then explored whether they are more 
likely to pertain to orphan drug and rare disease characteristics, identified from key reports 
and official documents defining rare diseases and highlighting their common 
characteristics.(20, 21). 
Results 
Value judgment classification framework  
When evidence is uncertain or incomplete, scientific value judgments are made about its 
acceptability. Societal preferences are also accounted for by HTA approaches. These pertain 
to giving preference to certain (non-quantifiable) aspects of living with a disease or taking a 
treatment, which are translated into prioritising certain groups of patients over others, which 
can be elicited or not.(6, 7) These preferences are typically elicited by a group of 
representative citizens (e.g. NICE’s Citizens Council) or are enshrined within legislation. 
Examples of elicited preferences include the “SMC modifiers”, or disease severity in Sweden 
defined “on the basis of the relevant, initial condition and risk of permanent injury, ultimately 
death without treatment. All the positive effects the medicine has on people’s health and 
quality of life are accounted for”.(22) Non-elicited preferences, referred to as social value 
judgments, originate from the individual appraisal committee member’s value judgment 
based on their experience or on what they believe society would prefer, and are usually made 
as part of the deliberative processes of HTA. Both scientific and social value judgments are 
defined as “other considerations” within the scope of this study (Table 1).  
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Table 1. HTA bodies sampling and classification framework of scientific assessment and of social or societal preferences 
HTA Body Scientific assessment Social or societal preferences ICER 
HTA criteria & 
perspective 
-quantified- 
Scientific value 
judgments 
-non-quantified- 
Preferential 
status 
 
-elicited- 
Orphan drug 
preferential 
status  
-elicited- 
Social value 
judgments 
 
-non-elicited- 
✔ Acceptable 
★ Acceptable, accounting 
for other factors 
✗ Not acceptable unless 
exceptional circumstances 
England 
National 
Institute for 
Health and 
Care 
Excellence -  
NICE 
Clinical cost-
effectiveness 
(ICER) 
 
National Health 
Service (NHS) 
and Personal 
Social Services 
(PSS) 
perspective 
As part of the 
deliberative 
process, judgment 
about the 
acceptability of 
uncertain or 
incomplete 
evidence, including 
about the 
assumptions made 
(e.g. economic 
modelling), or 
about certain non-
quantified 
considerations 
around treatment 
and disease 
characteristics. 
 
Examples:  
- health-related 
End-of-life 
supplementary 
advice: 
- life-
threatening  
- small patient 
numbers 
- life-
extending  
  As part of the 
deliberative process, 
giving preference to 
certain non-
quantifiable 
considerations around 
treatment and disease 
characteristics when 
these have not been 
elicited from a 
representative 
population of 
citizens. Preference 
originates from the 
individual judgments 
of the appraisal 
committee based on 
their experience or on 
what they believe 
society would prefer 
or on conclusions of 
✔ < 20,000/QALY 
★ £20-£30,000/QALY 
✗ > £30,000/QALY (e.g. 
end-of-life treatment) 
Scotland 
Scottish 
Medicines 
Consortium -  
SMC 
Clinical cost-
effectiveness 
(ICER) 
 
National Health 
Service (NHS) 
and Personal 
Social Services 
(PSS) 
perspective 
  SMC 
modifiers: 
- life- 
threatening 
- life-
extending 
- quality of 
life 
improvement 
- curative 
intent 
✔ no threshold, but 
accounts for NICE 
threshold 
★ no threshold, but 
accounts for NICE 
threshold 
✗ no maximum threshold, 
but accounts for NICE 
threshold 
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quality of life 
- administration 
benefits 
- uncertain resource 
use 
- clinical pathways 
- discount rate 
- disease severity 
- unmet need citizen's councils / 
juries. 
 
Examples:  
- orphan status 
- unmet need 
- treatment 
innovativeness  
- disease severity 
Sweden 
Dental and 
Pharmaceutical 
Benefits Board 
- TLV 
Human value, 
need and 
solidarity 
principle, and 
cost-
effectiveness 
(ICER) 
 
Societal 
perspective 
Disease 
severity & 
unmet need 
  ✔ no threshold, but based 
on previous decisions 
average of drugs approved 
is Eur 36,000/QALY 
★  no threshold, but based 
on previous decisions 
average of drugs approved 
is Eur 36,000/QALY, up 
to Eur 90,000/QALY 
✗ no maximum threshold, 
but based on previous 
decisions ICER greater 
than EUR 90,000/QALY 
France 
Haute Autorité 
de Santé - 
HAS 
Clinical benefit 
(SMR) and 
relative 
improvement in 
clinical benefit 
(ASMR) 
  Public Health 
Act 2004, 
recognising 
rare diseases 
as a national 
priority 
No threshold exists though 
a two-stage process is used 
where coverage relies on 
the clinical benefit (SMR) 
and the price negotiation 
uses the (relative) 
improvement in clinical 
benefit (ASMR). 
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Study drugs and HTA recommendation 
The study included ten drugs for specific indications. The five inpatient drugs were not 
appraised by TLV, whom only appraised outpatient drugs at the time of the study. Based on 
the indicative cost-effectiveness thresholds (Table 1), some treatments with an ICER greater 
than the respective threshold received a positive recommendation: mannitol dry, azacitidine, 
lenalidomide, mifamurtide, and trabectedin for NICE; azacitidine, lenalidomide, mifamurtide, 
and imatinib for SMC; everolimus, mifamurtide and romiplostim for TLV. In some instances, 
the ICERs were improved with a Patient Access Scheme that provided a confidential 
discounted drug price. In France, where coverage is disconnected from the ICER and no 
threshold exists, only one case was rejected for reimbursement (mifamurtide), three drugs 
received an ASMR V where no additional benefit was recognised (ofatumumab, mannitol 
dry, trabectedin), and the remainder were considered to provide additional benefits (Table 2).  
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Table 2. ICER and coverage decisions (SMR and ASMR in France) 
 
Drug 
Indication
ICER Decision ICER Decision ICER* Decision SMR ASMR
Eltrombopag
Chronic thrombocytopenic 
purpura
✗ £104,000-
£116,000/QALY 
(standard care)
Reject ✔CUA dominant 
compared to 
romiplostim
(SMC modifiers)
Restrict
(Subgroup severe 
ITP and high risk of 
bleeding)
✔CMA dominant 
compared to 
romiplostim
(severity)
Restrict
(Re-
assessment, 
and for hospital 
use)
Important II
Ofatumumab
Chronic lymphocytic 
leukemia
✗ £50,300 - 
£81,500/QALY, 
depending on subgroup
(PAS)
Reject ✗£108,815/QALY Reject Moderate V
Mannitol dry
Cystic fibrosis
✗£50-£80,000/QALY 
rhDNase
★< £30,000/QALY no 
rhDNase
Restrict
(Subgroup with no 
rhDNase, rapid decline 
of lung function, 
intolerant to osmotic 
agents)
★£20,736/QALY no 
rhDNase
Reject Weak V
Everolimus
Renal cell carcinoma 
(2nd line, advanced)
✗£51,700/QALY
(EoL, PAS)
Reject ✗£61,330/QALY Reject ★Cost/QALY high but 
justified given the 
severity of the disease
(severity)
List Important IV
Azacitidine
Myelodysplastic syndrome
✗£47,200/QALY
(best case scenario)
(EoL, PAS)
List ✗£51,275/QALY
(SMC modifiers, PAS)
List Important II
Lenalidomide
Multiple myeloma 
(2nd, 3rd line)
✗two or more prior 
therapies: 
£41,300-43,800/QALY
(chemo alone)
(EoL, PAS)
Restrict
(Subgroup 3rd line)
✗£34,286-
£41,381/QALY
(chemo alone)
(SMC modifiers)
Restrict
(Subgroup 3rd line)
✔SEK290,000/QALY 
(bortezomib)
= EUR 32,000/QALY
(severity) 
List Important III
Mifamurtide
Osteosarcoma
✗£36,000/QALY
(1.5% discount, PAS)
List ✗£48,579/QALY
(1.5% discount, PAS)
List ★-✗SEK 700,000-
900,000/QALY
= EUR 77-99,000/QALY 
(severity, 3% discount)
List Insufficient DNL
Trabectedin
Soft tissue sarcoma
✗£34,500/QALY
(EoL, PAS)
List ★£36,841/QALY
(PAS)
Reject Important V
Imatinib
Gastro-intestinal stromal 
tumours (GIST)
(adj. unresectable and/or 
metastatic)
★£21-£23,000/QALY 
(significant and 
moderate risk of 
recurrence)
Reject ★£20,655/QALY 
(SMC modifiers)
Restrict
(Subgroup of 
patients with high 
risk of recurrence 
following complete 
resection)
Important III
Romiplostim
Chronic thrombocytopenic 
purpura
✔High risk of bleeding
< £20,000/QALY 
slenectomised 
= £30,000/QALY non-
splenectomised
(PAS)
Restrict
(Subgroup with high 
risk of bleeding, risk 
management plan)
✔High risk of 
bleeding:
£15,220/QALY 
splenectomised 
£16,673/QALY non-
splenectomised
 (standard care)
(SMC modifiers)
Restrict
(Subgroup with high 
risk of bleeding, 2nd 
line or when 
surgery is 
contraindicated)
★SEK 400-
600,000/QALY
= EUR 44-66,000/QALY
Restrict
(Re-assessment 
& risk 
management 
plan)
Important II
✔
★
✗
HAS
France
SMC
Scotland
TLV
Sweden
NICE
England
Acceptable ICER: 
- within 20,000/QALY for NICE. 
- SMC: no threshold, but accounts for NICE threshold
- TLV: no threshold, but based on previous decisions average of drugs approved is Eur 36,000/QALY
Acceptable ICER accounting for other factors:
- NICE: £20-£30,000/QALY
- SMC: no threshold, but accounts for NICE threshold
- TLV: no threshold, but based on previous decisions average of drugs approved is Eur 36,000/QALY, up to Eur 90,000/QALY
High ICER, likely not acceptable except if exceptional circumstances:
- NICE: > £30,000/QALY (e.g. end-of-life treatment)
- SMC: no maximum threshold, but accounts for NICE threshold
- TLV: no maximum threshold, but based on previous decisions ICER greater than EUR 90,000/QALY
*1 SEK = 0.110202 EUR
Legend: PAS: Patient Access Scheme; EoL: End-of-Life treatment; severity: disease severity considered high; QALY: quality-adjusted life years; ICER: incremental 
cost-effectiveness ratio; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits 
Board; HAS: Haute Autorite de Sante.
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 “Other considerations”: an overview 
125 individual “other considerations” were coded and grouped into 10 categories (Figure 1). 
These were either provided as background information, by experts, or were considered 
important for the decision. 94 of these 125 codes were included by NICE and used 173 times 
across all 10 cases (e.g. one may have been coded for more than one drug), followed by 24 
codes used 67 times by HAS, 23 codes used 50 times by SMC, and 33 codes used 56 times 
by TLV. The most commonly reported disease characteristic related to the nature of the 
disease, its rarity and unmet need. The most common treatment characteristics related to its 
type of benefit, innovative nature, indirect benefit or the non-significance of its adverse 
events. 
 
Figure 1. Proportion of drugs that accounted for a category of “other considerations”, per 
cluster 
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 “Other considerations” as pivotal factors in the decision processes 
A proportion of these 125 “other considerations” were also put forward as one of the main 
reasons for their decisions. These represent 18% of those put forward by NICE (32 of 173), 
24% by SMC (12 of 50), 34% by TLV (19 of 56), and 100% by HAS (67 of 67) (Table 3). 
For the purpose of HAS, these “other considerations” were mainly discussed in the 
conclusions of the Transparency Committee when assessing the ISP and have all been 
considered as main reason for the final recommendation. 
 
A proportion of these (e.g. cases with a superscript in Table 3) pertained to those preferences 
elicited by each HTA body (Table 1), where higher ICERs or uncertain evidence may be 
accepted. Four drugs were eligible under the NICE end-of-life supplementary advice, three of 
which were considered cost-effective with an ICER ranging between £34,000-
£47,000/QALY (lenalidomide, azacitidine, trabectedin), and the fourth (everolimus) not cost-
effective with £51,700/QALY. Weaknesses in the economic model were deemed acceptable 
because of the SMC modifiers in four cases (eltrombopag, imatinib, azacitidine, 
lenalidomide). For HAS, all study drugs were recognised as targeting patients with rare 
diseases and assessed within the framework of one or more ministerial plans. In Sweden, 
higher ICERs were accepted due to the severity of the conditions.  
 
Cases without a superscript in Table 3 represent the additional (non-quantified or non-
elicited) “other considerations” put forward as one of the main reasons for the decision, 
relating to the scientific and social value judgments made. For NICE, these included the 
treatment’s unmet need for lenalidomide, mifamurtide and mannitol dry, its innovativeness 
for azacitidine and mifamurtide, and the severity of the disease for mannitol dry. 
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Additionally, the impact on families’ and friends’ quality of lives, the rarity of the disease, 
and the ability to contribute to society and live an active and fulfilling life were also 
highlighted for mifamurtide. For SMC, these included the oral administration benefit, the 
orphan status and unmet need (e.g. additional treatment option) for eltrombopag, the potential 
reduction in resource use for romiplostim, and the life-extending nature of the treatment for 
mannitol dry and azacitidine. Similarly, TLV also valued certain treatment characteristics, 
such as its oral administration benefit (e.g. eltrombopag), novel mechanism of action (e.g. 
eltrombopag, romiplostim), orphan status (e.g. eltrombopag), and the impact of the disease on 
quality of life and daily activities (e.g. eltrombopag, romiplostim, lenalidomide). Unmet need 
was also recognised (e.g. eltrombopag, romiplostim), and in one case, TLV acknowledged 
the changing environment in clinical practice (e.g. lenalidomide). For HAS, both disease and 
treatment characteristics were put forward for all drugs, namely around the nature of the 
disease, the need for treatment alternatives, and the direct or indirect benefit from taking the 
treatment. In France, orphan drugs are presumed to be innovative and thus subject to fast-
track HTA consideration. In the assessment, the innovativeness of a drug is recognized for 
those drugs with ASMR I-III. 
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Table 3. “Other considerations” as pivotal factors in the decision 
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Scientific value 
judgment
-non-quantified-
Social value 
judgment
-non-elicited-
National priority
- Rare disease plan
- Cancer plan
- Plan for improving qol in patients with chronic diseases
- Public Health Law 2004
- Falls in the scope of the fight against cancer
HASrare
HASrare
HASrare
HASrare
HASrare
HASrare HAS
rare
HASrare
HASrare HAS
rare
HASrare
HASrare
HASrare
HASrare
HASrare
HASrare
Issues around current treatment alternatives
- changing treatment pathways TLV ★
Disease nature affecting the patient
-Short life expectancy
- Disease severity
- Disease with a poor prognosis
- Serious condition
- Life threatening
- Incurable
- Requires life long treatment
- Affects quality of life
- Affects daily activities and functional capacity
HAS, TLVseverity
TLV
HAS
TLV, HAS
TLV
TLVseverity
HAS
TLV
HAS, TLV
HAS, TLV
NICEend
TLVseverity
HAS
HAS
NICEend, HAS
TLVseverity
HAS
TLV
NICEend, HAS
HAS
HAS
NICE
HAS
HAS
HAS
HAS
HAS, TLV
severity
HAS HAS
NICEend
HAS
HAS
★  
★  
★
★
★
★
★
★
★
Disease nature affecting the patient's surrounding
- Impact on quality of life of family and friends NICE ★
Rarity, orphan status, small patient population
- Small patient population
- Minor public health burden because of rarity 
- Orphan status
TLV
HAS
SMC
HAS
NICEend NICEend
SMCmodifiers
NICEend
SMCmodifiers
HAS
SMCmodifiers
HAS
NICE
HAS
NICEend
HAS
★
Unmet need 
- Importance of new treatment options
- Few developments in last years
- No (satisfactory) alternatives exist
- Alternatives exist
- Need to improve therapeutic management
- Few therapeutic options
- New treatment would offer new options
- Alternative treatments not routinely available 
TLV
HAS
SMC
HAS
TLV
HAS
HAS
NICE
HAS
NICE
NICE
HAS
NICE
HAS
HAS
HAS
HAS
 ★
Type of treatment benefit
- Curative
- Palliative
- Preventive
- Symptomatic
- Salvage treatment
- Life-extending
- Benefit extended over a long period
HAS HAS, SMCmodifiers HAS
NICEend
HAS
NICEend
HAS
NICEend,SMCmodifiers
HAS
SMCmodifiers
HAS 
SMC
NICEdiscount, HAS
SMCmodifiers
NICE
HAS
HAS
HAS
NICEend
★
Innovative nature of the treatment
- Important advance
- Novel mechanism of action
- Significant innovation for a rare disease
- New class of drugs
- Potential valuable new therapy
- Oral administration advantage
HAS
TLV
TLV, SMC, HAS
TLV
NICE
NICE
NICE
NICE
★
Indirect benefits from taking the treatment
- Ability to lead an active and fulfulling life
- Ability to contribute to society
- Significant impact on morbidity
- Significant impact on mortality
- Significant impact on quality of life
- Resource use reduction HAS, SMC HAS
HAS
HAS
HAS
HAS
NICE
NICE
★
★
★
★
★
★
Legend: end: NICE End-of-life supplementary advice; severity:severe disease; modifiers: SMC modifiers; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Benefits 
Board; HAS: Haute Autorite de Sante
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Stakeholder input 
 
No mention of stakeholder input was found for TLV given that this is done informally and 
generally not documented. In contrast, formal channels exist to collect stakeholder input 
during the technology appraisal processes through the Public Involvement Programme (PIP) 
at NICE, the Patient and Public Involvement Group (PAPIG) at SMC, and the procedures for 
rapporteurs at HAS. In the latter case, the Transparency Committee meeting minutes note 
how many outside experts provided input but not the content of their advice. 
 
 “Other considerations” were provided by stakeholders in 116 of the 175 identified in the 
NICE appraisals. 41% of these (n = 116) were provided by clinical experts, 21% by patient 
representatives, and 35% by both clinical experts and patient representatives. Clinical experts 
provided information about the nature of the disease affecting the patient (27%), issues 
around current treatment alternatives (13%), the treatment’s unmet need (11%) and 
innovativeness (10%), and the non-significance of adverse events (10%). Patient 
representatives provided information about the nature of the disease affecting the patient 
(33%), the non-significance of adverse events (14%), the indirect benefits from taking the 
treatment (12%) and the patient’s unmet need (11%). In Scotland, all drugs except 
trabectedin and imatinib received a Patient Interest Group submission. The detail of these 
submissions was not publicly available. Clinical input was recorded in the reports for two 
cases, commenting on the treatment pathways in terms of symptoms (e.g.eltrombopag) and 
unlicensed comparators (e.g romiplostim).  
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Orphan drugs and special status  
Table 4 represents the subcategories of “other considerations” identified in the sampled drugs 
(rows) and whether they pertain to certain characteristics specific, but not limited to, rare 
disease and orphan drugs (columns). Unmet need is more likely to characterise rare diseases 
given the scarcity of relevant knowledge and expertise and the fact that often no effective 
cure exist. This is due to issues around the diagnosis of some of these rare diseases, the 
complex and unknown nature of these conditions, together with the lack of coordination 
amongst centres of expertise at EU- and international-levels, and the lack of knowledge 
around best practices.(23) Further, given that orphan drugs often do not have effective cure, 
treatments for rare diseases are more likely to be innovative. On this basis, the “other 
considerations” that were put forward as one of the main reasons for the final decision 
identified previously, therefore influencing the final decision, may favour orphan drugs 
compared to drugs to treat normal conditions. This was seen, for example, with “unmet need” 
for lenalidomide, mifamurtide and mannitol dry by NICE, and for eltrombopag, romiplostim 
by SMC. 
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Table 4. Special status of orphan drugs 
  
Special 
status? 
Disease or treatment characteristic specific to rare diseases and orphan drugs 
Subcategories of "other considerations" 
(non-quantifiable or non-quantified) 
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Nature of the disease affecting the patient  
eg disease severity, impact on quality of life 
and daily activities 
★       ✔ ✔ ✔ ✔ ✔ ✔ 
Nature of the disease affecting the patients' 
surrounding 
eg impact of the disease on the families' 
quality of lives, anxiety, limiting life choices 
★                 ✔ 
Rarity, orphan status, small patient numbers ✔ ✔                 
Unmet need 
eg no or few treatment alternatives exist, 
treatment pathway unclear 
★   ✔       ✔       
Type of treatment benefit 
eg curative, life extending 
★           ✔ ✔ ✔   
Innovative nature of the treatment 
eg new mechanisms of action 
★   ✔       ✔       
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Indirect benefit from the treatment 
eg quality of life improvement, ability to live 
normal lives, improved symptoms, 
administration benefit 
★       ✔ ✔   ✔ ✔ ✔ 
✔ Characteristic specific to rare diseases and orphan drugs 
★ Characteristics likely specific to rare diseases and orphan drugs 
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Discussion 
This study identified the value judgments made for ten orphan drugs in four countries in 
order to understand how they influenced the assessment process. The study also identified 
cases when these “other considerations” were provided by different stakeholders, by type of 
information provided, and when they related to rare disease characteristics. Implications are 
discussed here and focus on five topical areas: (a) the classification framework, (b) existing 
literature, (c) determinants of social value, (d) accountability for reasonableness, and (e) 
orphan drugs and special status.   
 
One of the significant contributions of this study is the proposed classification framework of 
the value judgments bring made during HTA processes (Table 1). It allows to highlight needs 
for further research (when evidence is incomplete or preferences are non-elicited). If they 
continue not to be elicited or quantified, retrospectively identifying these to prospectively 
create a taxonomy of criteria may facilitate their being used more consistently when similar 
scenarios are encountered in the future. For example, NICE emphasised the impact of 
osteosarcoma on families’ and friends’ lives when assessing mifamurtide, or SMC and TLV 
recognised the “oral administration benefit” when assessing eltrombopag. These are non-
quantified or non-elicited criteria for which preference could be given in future cases by their 
inclusion in the taxonomy of criteria to be accounted for. This is all the more important when 
considering the extent to which these considerations are different across countries and likely 
also across decision-making bodies within one HTA agency. These differences are either a 
consequence of agency-specific value preferences,(24) or of committee-specific preferences 
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reflecting the composition of the decision panel and their individual judgments driven by 
their experiences, and it is therefore important to improve the consistency in their use. 
 
The different “other considerations” identified and their classification into sub-categories and 
clusters are in line with findings from the literature on (social) value judgments. Schwappach 
(2002) divides the determinants of social value into patient and treatment characteristics.(25) 
Our study clustered these determinants in a similar manner and takes one step further by 
applying this same classification to both social and scientific value judgments. Second, a 
number of individual social values were identified in the literature. One study in England 
used qualitative techniques to define these, where respondents agreed to favour need, 
preventive care, quality of life, health improvement and life expectancy, in addition to not 
favouring certain populations according to age or socio-economic status.(26) Generally there 
is agreement about what these social values are, but the determinants of social value remain 
broadly defined and no exhaustive list of these exists.  When comparing these results to the 
topics defined in several of the EUnetHTA Core Model® domains, commonalities and 
differences are seen.(27) The topics included in the ethical domain relate to societal 
preferences and the norms or values from using a technology, which corresponds to, in this 
study, the disease nature affecting patients and their surroundings, and recognised unmet 
need in terms of how the introduction of a new technology affects the distribution of health 
care resources.  However, the judgment about the magnitude of this unmet need was clearly 
captured in our results, but does not seem to be explicitly accounted for in the Core Model®.  
Topics in the social domain relate to the types of resources required and the experiences, 
actions and reactions from patients when using the technology, and correspond to the elicited 
societal preferences (e.g. rare diseases), and to the treatment’s direct and indirect benefits, 
including if the adverse events are manageable (e.g. patients’ experiences).  Topics in the 
organisational domain relate to the consequences on resources or the organisational aspects 
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from using the technology, and would correspond to issues with current treatment alternatives 
or around clinical practice.  The innovative nature of the treatment, identified in our study, is 
captured within the technical characteristics of the technology in the Core Model®, though 
no explicit definition is provided.(27) The value judgments identified in this study therefore 
correspond to the different domains included in the Core Model®, and further contribute to 
understanding their determinants in how they are expressed in practice.  
 
Given that the determinants of social value are only broadly outlined, this study contributes to 
better defining these. For example, “unmet need” is a determinant of social value. It is 
accounted for in the weighing of disease severity by TLV, as one of the SMC modifiers, and 
discussed within NICE Citizen Council meetings. Nevertheless, no clear definition of unmet 
need exists. Our results captured the variety of ways of expressing “unmet need” (Table 3), 
which can be used to define it. Another example is disease severity, for which no single 
definition exists. It is characterised by a number of determinants, which include the impact on 
quality of life and mobility, or considerations of life expectancy.(8, 28) Severity is included 
into HTA either through a weighing of the QALY (or of other measures of HTA) or as part of 
the deliberative process.(8) The latter would apply to our study countries since no specific 
weighing for severity was seen, including in Sweden where it is explicitly accounted for 
despite the definition of disease severity being broad (as noted earlier). Our results identified 
the various forms of expressing severity, which can be used to better define severity for 
future cases. For TLV, these included: the life-threatening nature of the disease, the negative 
impact on daily activities including functional capacity and on quality of life, and the short 
life expectancy from having the disease. In France, where no ICER or threshold exist, 
informal methods are used to incorporate societal and political values into the assessments. 
This is explicit in the evaluation of the public health value (intérêt de santé publique) of drugs 
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as part of the coverage evaluation (SMR), however, whether these determinants of (social) 
value are accounted consistently across cases is another question, which could be partly 
addressed by applying the taxonomy of criteria. 
 
For a resource allocation decision to be accountable for reasonableness, the process should be 
transparent and public, based on reasons that are relevant, decisions should be revisable when 
new evidence is available, and the process should allow for these conditions to be 
enforced.(9, 29) This usually takes place during the deliberative process of HTA, during 
which the Committee discusses the evidence and accounts for stakeholder opinion until a 
decision is made. The decision and reasons for the decision should then be documented in the 
HTA report, most often publicly available, as is the case with our study countries. In terms of 
stakeholder input, a clear process exists at NICE and SMC where they are given the 
opportunity to voice their concerns or opinions. Our analysis confirmed that this is well-
reported for NICE (given the high number of “other considerations” provided by different 
experts), but is not as detailed in SMC’s summary of advice, probably because it is a less 
detailed report. HAS has specific procedures governing outside experts (rapporteurs) who 
provide advice and input in the evaluation process. For TLV, no official procedures exist, 
although some of the key stakeholders are represented within the Appraisal Committees (e.g. 
clinical experts). Generally, the type of input from these stakeholders could be better 
documented or transparent. Some argue that it is not sufficient to have a formal procedure to 
account for stakeholder input and value judgments, but that it should also be clear how these 
have influenced the decision, which is often lacking.(8) Our results further confirm this in the 
number of “other considerations” (from stakeholders or not) identified, where it is not 
entirely clear how these factors contributed to the decisions particularly in those cases where 
these were (non-elicited or non-quantified) value judgments. The taxonomy of criteria 
developed together with the type of input from different stakeholders may help understand 
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the criteria that are relevant to decision-making and their sources that go beyond routine 
methods of assessing clinical benefit and ICERs.  
 
Little agreement exists on whether patients with rare diseases requiring orphan drug 
treatments deserve a preferential status.(13-15) Nevertheless, governments recognise the 
difficulties in appraising these treatments and the fact that they should be treated differently. 
In France, patients with orphan diseases have a preferential status, but their needs go beyond 
drugs. Only recently, NICE and SMC have implemented new procedures for end-of-life and 
ultra-orphan drugs. The treatment’s additional benefit and other elements not captured by the 
ICER (e.g. unmet need, disease severity, added value the patient and surrounding) are now 
accounted for by SMC, together with patient and clinical engagement. These other elements 
correspond to the “other considerations” identified in this study. Similar questions are arising 
in Sweden, where a consultation on how to appraise orphan drugs has recently been issued. 
Further, in NICE’s recent consultation on value-based pricing, they attempted to find novel 
approaches to capturing burden of illness and other issues. They concluded that approaches to 
adjusting the QALY were insufficient, whereby explicitly accounting for these additional 
criteria is essential for decision-making. This study provides an alternative to the issue of 
preferential status by accounting for the non-elicited or non-quantified “other considerations” 
that influenced previous decisions, and query whether it would be worth eliciting preferences 
for these. This could then feed into novel approaches in assessing orphan drugs (e.g. MCDA).   
Conclusions 
This study systematically identified the scientific and social value judgments made in four 
countries for a sample of orphan drugs, and explored how they influenced the deliberative 
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process of HTA. The proposed classification framework of these value judgments was used 
to identify needs for further research and to improve consistency in their use across cases. 
This was then used to address different issues around identifying and better defining the 
determinants of social value or how to improve the lack of accountability for reasonableness 
particularly in cases when it was not clear how the “other considerations” identified 
influenced the decisions. It also provided a way forward to eliciting whether these orphan 
drugs deserve a special status by eliciting preferences around some of the social value 
judgments made which are more likely to pertain to orphan compared to non-orphan drugs, 
rather than focusing on the opportunity cost of these. Given the challenges in producing 
robust evidence for orphan drugs due to the small patient numbers and heterogeneity of the 
diseases, scientific and social value judgments are unavoidably part of the decision processes 
for these drugs. Their identification through the application of this framework enables us to 
create a taxonomy of criteria relevant to these decision-making processes, which go beyond 
routine methods for HTA. 
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